This report describes one 72-year-old woman treated for ANCA-associated vasculitis and Evans syndrome. She also suffered a cerebral infarction. Doctors used corticosteroids, intravenous immunoglobulin, therapeutic plasma exchange, and cyclophosphamide. This combination of therapies is common for severe immune system disorders but was applied here to a single individual.
During the hospital stay, her renal and hematological parameters stabilized. This means kidney function and blood cell counts improved or held steady. However, her neurological deficits and thrombocytopenia persisted. These issues did not resolve during the reported period.
The patient experienced a SARS-CoV-2 infection. This adverse event occurred while she received immunosuppressive therapy. The main reason to be careful is the balance between fighting disease and managing infection risk. Early testing for ANCA in stroke cases with systemic involvement is vital. Management requires careful attention to these risks.
Readers should take from this that outcomes vary greatly in individual cases. This report is a case study and literature review. It does not provide proof that these treatments work for everyone. More data is needed to understand typical results.